Document is current
Any future updates will be listed below
-
Authors
Garrido-Castro, Ana C. https://orcid.org/0000-0002-5989-6636
Regan, Meredith M.
Niman, Samuel M.
Nakhlis, Faina https://orcid.org/0000-0003-4752-0161
Remolano, Claire
Rosenbluth, Jennifer M.
Block, Caroline
Warren, Laura E. https://orcid.org/0000-0002-7418-6405
Bellon, Jennifer R.
Yeh, Eren
Harrison, Beth T. https://orcid.org/0000-0002-8341-2961
Troll, Elizabeth
Lin, Nancy U.
Tolaney, Sara M. https://orcid.org/0000-0002-5940-8671
Overmoyer, Beth https://orcid.org/0000-0003-4438-7000
Lynce, Filipa https://orcid.org/0000-0001-6615-7076
-
Funding
Funding for this research was provided by:
This study was funded by the Dana-Farber Cancer Institute IBC Research Fund and the Reardon Family Fund.
- License Information
-
More Information
Article History
Received: 20 October 2022
Accepted: 19 May 2023
First Online: 2 June 2023
Competing interests
: The authors report the following potential financial competing interests: Consulting/Advising Role: Novartis (S.M.T.), Pfizer (S.M.T., F.L.), Merck (S.M.T.), Eli Lilly and Company (S.M.T.), Nektar Therapeutics (S.M.T.), NanoString Technologies (S.M.T.), AstraZeneca (S.M.T., M.M.R., N.U.L., F.L.), Puma Biotechnology (S.M.T., N.U.L.), Genentech/Roche (S.M.T.), Eisai (S.M.T.), Sanofi (S.M.T.), Bristol Myers Squibb (S.M.T., M.M.R.), Seattle Genetics (S.M.T., N.U.L.), Odonate Therapeutics (S.M.T.), OncoPep (S.M.T.), Kyowa Hakko Kirin (S.M.T.), Samsung Bioepis (S.M.T.), CytomX Therapeutics (S.M.T., F.L.), Daiichi Sankyo (S.M.T., N.U.L., F.L.), Athenex (S.M.T.), Gilead Sciences (S.M.T.), Mersana (S.M.T.), Certara (S.M.T.), Chugai Pharma (S.M.T.), Ellipses Pharma (S.M.T.), Infinity (S.M.T.), 4D Pharma (S.M.T.), OncoSec Medical Inc. (S.M.T.), BeyondSpring Pharmaceuticals (S.M.T.), OncXerna (S.M.T.), Zymeworks (S.M.T.), Zentalis (S.M.T.), Blueprint Medicines (S.M.T.), Reveal Genomics (S.M.T.), ARC Therapeutics (S.M.T.), Ipsen Biopharmaceuticals (M.M.R.), DebioPharm (M.M.R.), Tolmar Pharmaceuticals (M.M.R.), Denali Therapeutics (N.U.L.), Prelude Therapeutics (N.U.L.), Olema Pharmaceuticals (N.U.L.), Aleta BioPharma (N.U.L.), Affinia Therapeutics (N.U.L.), Voyager Therapeutics (N.U.L.), Janssen (N.U.L.), Blueprint Medicines (N.U.L.), OncoSec Medical, Inc. (FL). <i>Institutional Research Funding</i>: Genentech/Roche (S.M.T., N.U.L.), Merck (S.M.T., ACG-C, N.U.L.), Exelixis (S.M.T.), Pfizer (S.M.T., M.M.R., N.U.L.), Eli Lilly and Company (S.M.T.), Novartis (S.M.T.), Bristol Myers Squibb (S.M.T., M.M.R.), Eisai (S.M.T., FL), AstraZeneca (S.M.T., A.C.G.C., M.M.R., N.U.L., FL), NanoString Technologies (S.M.T.), Cyclacel Pharmaceuticals (S.M.T.), Nektar Therapeutics (S.M.T.), Gilead Sciences (S.M.T., A.C.G.C., FL), Odonate Therapeutics (S.M.T.), Sanofi (S.M.T.), Seattle Genetics (S.M.T., N.U.L.), Ipsen Biopharmaceuticals (M.M.R.), TerSera Therapeutics (M.M.R.), DebioPharm (M.M.R.), Pierre Fabre (M.M.R.), Roche (M.M.R.), Bayer (M.M.R.), Zion Pharmaceuticals (N.U.L.), Olema Pharmaceuticals (N.U.L.), Daiichi-Sankyo (A.C.G.C.), Zenith Epigenetics (A.C.G.C.). <i>Stock and Ownership Interests</i>: Artera, Inc. <$50,000 and <5% as it relates to consulting activities; options are not currently valued or in-hand (N.U.L.). <i>Speaker Honorarium</i>: Varian (J.R.B.). Royalties: UpToDate, Inc. (N.U.L.). <i>Travel support</i>: Roche/Genentech (A.C.G.C.). The authors have no non-financial competing interests to declare.
